These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. Larter CZ; Chitturi S; Heydet D; Farrell GC J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324 [TBL] [Abstract][Full Text] [Related]
4. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)? Caldwell SH; Ikura Y; Iezzoni JC; Liu Z J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S11-9. PubMed ID: 17567458 [TBL] [Abstract][Full Text] [Related]
5. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery. Verna EC; Berk PD Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297 [TBL] [Abstract][Full Text] [Related]
6. Role of mitochondria in non-alcoholic fatty liver disease. Pessayre D J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S20-7. PubMed ID: 17567459 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. Roden M Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):335-48. PubMed ID: 16932311 [TBL] [Abstract][Full Text] [Related]
8. Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production. Grefhorst A; Hoekstra J; Derks TG; Ouwens DM; Baller JF; Havinga R; Havekes LM; Romijn JA; Kuipers F Am J Physiol Gastrointest Liver Physiol; 2005 Sep; 289(3):G592-8. PubMed ID: 15817811 [TBL] [Abstract][Full Text] [Related]
15. The role of the lipogenic pathway in the development of hepatic steatosis. Postic C; Girard J Diabetes Metab; 2008 Dec; 34(6 Pt 2):643-8. PubMed ID: 19195625 [TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Luyckx FH; Lefebvre PJ; Scheen AJ Diabetes Metab; 2000 Apr; 26(2):98-106. PubMed ID: 10804323 [TBL] [Abstract][Full Text] [Related]
17. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. den Boer M; Voshol PJ; Kuipers F; Havekes LM; Romijn JA Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):644-9. PubMed ID: 14715643 [TBL] [Abstract][Full Text] [Related]
18. Role of ChREBP in hepatic steatosis and insulin resistance. Denechaud PD; Dentin R; Girard J; Postic C FEBS Lett; 2008 Jan; 582(1):68-73. PubMed ID: 17716660 [TBL] [Abstract][Full Text] [Related]
19. Fish oil and argan oil intake differently modulate insulin resistance and glucose intolerance in a rat model of dietary-induced obesity. Samane S; Christon R; Dombrowski L; Turcotte S; Charrouf Z; Lavigne C; Levy E; Bachelard H; Amarouch H; Marette A; Haddad PS Metabolism; 2009 Jul; 58(7):909-19. PubMed ID: 19394055 [TBL] [Abstract][Full Text] [Related]
20. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Cusi K Clin Liver Dis; 2009 Nov; 13(4):545-63. PubMed ID: 19818304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]